We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Ampio Pharmaceuticals has reported that its AP-014 Phase I clinical trial of inhaled drug Ampion showed a 78% improvement in all-cause mortality in Covid-19 patients with respiratory distress.
Ampio Pharmaceuticals has revealed preliminary positive results of its AP-014 Phase I clinical trial that involves using of inhaled Ampion in treating respiratory distress in patients due to Covid-19.